Updates on the Development of a Highly Selective Inhibitor for HFpEF Treatment

Time: 11:00 am
day: Day Two


  • Deep dive into novel target for heart failure through a high content screening approach in iPS-derived cardiomyocytes
  • Working through multiple mechanisms of action including blocking fibrosis, inflammation and modulating metabolic pathways